Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01220726 · ClinicalTrials.gov registry record · Phase 3
Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction
A Phase 3 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT01220726 is a Phase 3 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 30 participants.
The verdict
NCT01220726, a Phase 3 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a prospective, randomized, double-blind study comparing intravesical injection of BOTOX to placebo. Study subjects will be randomized (1:1 ratio) to one of the following treatment groups:
Interventions
- DRUG Placebo
- DRUG Botox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2009-06 |
| Est. Completion | 2012-11-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01220726
The ClinicalTrials.gov registry entry for NCT01220726 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01220726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01220726 about?
NCT01220726 is a clinical study titled "Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction". This is a prospective, randomized, double-blind study comparing intravesical injection of BOTOX to placebo. Study subjects will be randomized (1:1 ratio) to one of the following treatment groups:
What is the current status of trial NCT01220726?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2009-06. Estimated completion is 2012-11-13.
What interventions are being tested in trial NCT01220726?
The interventions under investigation include: Placebo (DRUG), Botox (DRUG).
Who is sponsoring clinical trial NCT01220726?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.